Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dextran-conjugated saroglitazar
- Development stage
- Preclinical
- Lead developer
- University of Illinois, Urbana-Champaign
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intraperitoneal
01
Overview
Dextran-conjugated saroglitazar (also known as Dex-Saro or D-PPAR) is an investigational polymer-drug conjugate consisting of the dual PPARα/γ agonist saroglitazar covalently linked to a dextran nanocarrier via an esterase-cleavable carboxylester bond. Developed by researchers at the University of Illinois Urbana-Champaign, this nanomedicine is designed to selectively target pro-inflammatory macrophages within visceral adipose tissue depots. By delivering the PPARα/γ agonist directly to adipose tissue macrophages, the conjugate modulates macrophage phenotype, reduces systemic inflammation, and improves lipid and glucose metabolism. In preclinical models of diet-induced obesity, treatment with dextran-conjugated saroglitazar led to significant weight loss, improved glucose tolerance, reduced adipose tissue weight, and ameliorated hepatic steatosis without the typical side effects associated with systemic PPAR agonist administration.
- Other names
- D-PPARDex-Sarodextran-conjugated PPARα/γ agonist prodrug
02
Targets
PPARA (Peroxisome proliferator-activated receptor alpha)PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on dextran-conjugated saroglitazar.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dextran-conjugated saroglitazar.